Construction and Validation of a Progression‐Free Survival Prediction Model for Newly Diagnosed Multiple Myeloma Patients With 1q21 Gain/Amplification
Yuexuan Rao, Shiyou Li, Aoyang Yu, Wenjie Yu, Zhiyuan Yao, Huanxin Zhang, Zhenyu Li · 2026
Read Construction and Validation of a Progression‐Free Survival Prediction Model for Newly Diagnosed Multiple Myeloma Patients With 1q21 Gain/Amplification by Yuexuan Rao, Shiyou Li, Aoyang Yu, Wenjie Yu, Zhiyuan Yao, Huanxin Zhang, Zhenyu Li (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13546446.txt.
Description
Yuexuan Rao and co-authors build a score to forecast the course of a blood cancer. Their 2026 study covers 186 newly diagnosed myeloma patients who share one gene change, extra copies of a segment called 1q21. The goal is to guess how long treatment will hold the disease back.
Four traits drove the forecast: two blood markers, a gene loss, and the red-cell pigment level. The score, named HLBP, split patients into high and low risk groups with clearly unlike outcomes. It beat older staging systems in the tests run. Treatment gains also varied by risk group. The authors offer the score as a first guide, not a final rule.
Catalog record
| CREATOR | Yuexuan Rao, Shiyou Li, Aoyang Yu, Wenjie Yu, Zhiyuan Yao, Huanxin Zhang, Zhenyu Li |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 38 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |